Login Register Cart 0
Perspective

富替替尼:一种治疗胆管癌的有效且不可逆的成纤维细胞生长因子受体抑制剂

卷 31, 期 6, 2024

发表于: 24 May, 2023

页: [666 - 670] 页: 5

弟呕挨: 10.2174/0929867330666230416152913

摘要

胆管癌是一种罕见的癌症。福替替尼是一种不可逆的、有效的、选择性的成纤维细胞生长因子受体(FGFR 1-4)抑制剂。2022年9月30日，美国FDA首次批准福替替尼用于治疗不可切除、局部晚期或转移性肝内胆管癌患者，这些患者存在成纤维细胞生长因子受体2 (FGFR2)基因突变或其他类型的重排。该药的批准是基于3期临床试验结果，包括42%的总缓解率(ORR)和9.7个月的反应持续时间(DoR)。本文简要介绍了福替替尼的合成、理化性质、剂量、给药途径、作用机制、结合方式、药效学、药代动力学、药物相互作用、不良事件以及可能的耐药机制。

关键词: 胆管癌，福替替尼，成纤维细胞生长因子受体，药效学，药代动力学，药物相互作用。

« Previous Next »
[1]
Bergquist, A.; von Seth, E. Epidemiology of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol., 2015, 29(2), 221-232.
[http://dx.doi.org/10.1016/j.bpg.2015.02.003] [PMID: 25966423]
[2]
Razumilava, N.; Gores, G.J. Cholangiocarcinoma. Lancet, 2014, 383(9935), 2168-2179.
[http://dx.doi.org/10.1016/S0140-6736(13)61903-0] [PMID: 24581682]
[3]
Cardinale, V.; Semeraro, R.; Torrice, A.; Gatto, M.; Napoli, C.; Bragazzi, M.C.; Gentile, R.; Alvaro, D. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J. Gastrointest. Oncol., 2010, 2(11), 407-416.
[http://dx.doi.org/10.4251/wjgo.v2.i11.407] [PMID: 21160904]
[4]
Liu, C.; Wang, J.; Ou, Q.J. Possible stem cell origin of human cholangiocarcinoma. World J. Gastroenterol., 2004, 10(22), 3374-3376.
[http://dx.doi.org/10.3748/wjg.v10.i22.3374] [PMID: 15484322]
[5]
Khan, S.A.; Tavolari, S.; Brandi, G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int., 2019, 39(S1)(Suppl. 1), 19-31.
[http://dx.doi.org/10.1111/liv.14095] [PMID: 30851228]
[6]
Lowery, M.A.; Ptashkin, R.; Jordan, E.; Berger, M.F.; Zehir, A.; Capanu, M.; Kemeny, N.E.; O’Reilly, E.M.; El-Dika, I.; Jarnagin, W.R.; Harding, J.J.; D’Angelica, M.I.; Cercek, A.; Hechtman, J.F.; Solit, D.B.; Schultz, N.; Hyman, D.M.; Klimstra, D.S.; Saltz, L.B.; Abou-Alfa, G.K. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. Clin. Cancer Res., 2018, 24(17), 4154-4161.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0078] [PMID: 29848569]
[7]
Meric-Bernstam, F.; Bahleda, R.; Hierro, C.; Sanson, M.; Bridgewater, J.; Arkenau, H.T.; Tran, B.; Kelley, R.K.; Park, J.O.; Javle, M.; He, Y.; Benhadji, K.A.; Goyal, L. Futibatinib, an irreversible fgfr1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study. Cancer Discov., 2022, 12(2), 402-415.
[http://dx.doi.org/10.1158/2159-8290.CD-21-0697] [PMID: 34551969]
[8]
Sootome, H.; Fujita, H.; Ito, K.; Ochiiwa, H.; Fujioka, Y.; Ito, K.; Miura, A.; Sagara, T.; Ito, S.; Ohsawa, H.; Otsuki, S.; Funabashi, K.; Yashiro, M.; Matsuo, K.; Yonekura, K.; Hirai, H. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res., 2020, 80(22), 4986-4997.
[http://dx.doi.org/10.1158/0008-5472.CAN-19-2568] [PMID: 32973082]
[9]
Bahleda, R.; Meric-Bernstam, F.; Goyal, L.; Tran, B.; He, Y.; Yamamiya, I.; Benhadji, K.A.; Matos, I.; Arkenau, H.T. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors. Ann. Oncol., 2020, 31(10), 1405-1412.
[http://dx.doi.org/10.1016/j.annonc.2020.06.018] [PMID: 32622884]
[10]
Rizzo, A.; Ricci, A.D.; Brandi, G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives. Expert Opin. Investig. Drugs, 2021, 30(4), 317-324.
[http://dx.doi.org/10.1080/13543784.2021.1837774] [PMID: 33054456]
[11]
Goyal, L.; Chen, C.T.; Pierce, T.T.; Deshpande, V. Case 8-2021: A 34-year-old woman with cholangiocarcinoma. N. Engl. J. Med., 2021, 384(11), 1054-1064.
[http://dx.doi.org/10.1056/NEJMcpc2027092] [PMID: 33730458]
[12]
Lee, P.C.; Hendifar, A.; Osipov, A.; Cho, M.; Li, D.; Gong, J. Targeting the fibroblast growth factor receptor (fgfr) in advanced cholangiocarcinoma: Clinical trial progress and future considerations. Cancers, 2021, 13(7), 1706.
[http://dx.doi.org/10.3390/cancers13071706] [PMID: 33916849]
[13]
Doi, T.; Shitara, K.; Kojima, T.; Kuboki, Y.; Matsubara, N.; Bando, H.; Yoh, K.; Naito, Y.; Hirai, H.; Kurokawa, Y.; Kato, T.; Morizane, C. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci., 2022, 114(2), 574-585.
[http://dx.doi.org/10.1111/cas.15486] [PMID: 35838190]
[14]
Chen, L.; Zhang, Y.; Yin, L.; Cai, B.; Huang, P.; Li, X.; Liang, G. Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges. J. Exp. Clin. Cancer Res., 2021, 40(1), 345.
[http://dx.doi.org/10.1186/s13046-021-02156-6] [PMID: 34732230]
[15]
Duan, W.; Geng, M.; Wang, Y.; Ai, J.; Fan, J.; Dai, Y.; Ding, J. New compound having fgfr inhibitory activity and preparation and application thereof. WO2017215485A1 2017.
[16]
Sootome, H. Therapeutic agent for fgfr inhibitor-resistant cancer WO2015008844A, 2015.
[17]
Sagara, T.; Ito, S.; Otsuki, S.; Sootome, H. 3,5-disubstituted alkynylbenzene compound and salt thereof. US9108973B2 2013.
[18]
Qu, L.; Chen, X.; Wei, H.; Guo, M.; Dai, S.; Jiang, L.; Li, J.; Yue, S.; Chen, Z.; Chen, Y. Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Commun. Chem., 2022, 5(1), 5.
[http://dx.doi.org/10.1038/s42004-021-00623-x] [PMID: 36697561]
[19]
Yamamiya, I.; Lester, R.; Sonnichsen, D.; Mina, M.; He, Y.; Benhadji, K.A. Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, qt/qtc, phase 1 study in healthy subjects. Clin. Pharmacol. Drug Dev., 2023, 2(3), 304-313.
[http://dx.doi.org/10.1002/cpdd.1195] [PMID: 36404525]
[20]
Goyal, L.; Shi, L.; Liu, L.Y.; Fece de la Cruz, F.; Lennerz, J.K.; Raghavan, S.; Leschiner, I.; Elagina, L.; Siravegna, G.; Ng, R.W.S.; Vu, P.; Patra, K.C.; Saha, S.K.; Uppot, R.N.; Arellano, R.; Reyes, S.; Sagara, T.; Otsuki, S.; Nadres, B.; Shahzade, H.A.; Dey-Guha, I.; Fetter, I.J.; Baiev, I.; Van Seventer, E.E.; Murphy, J.E.; Ferrone, C.R.; Tanabe, K.K.; Deshpande, V.; Harding, J.J.; Yaeger, R.; Kelley, R.K.; Bardelli, A.; Iafrate, A.J.; Hahn, W.C.; Benes, C.H.; Ting, D.T.; Hirai, H.; Getz, G.; Juric, D.; Zhu, A.X.; Corcoran, R.B.; Bardeesy, N. TAS-120 overcomes resistance to atp-competitive fgfr inhibitors in patients with fgfr2 fusion–positive intrahepatic cholangiocarcinoma. Cancer Discov., 2019, 9(8), 1064-1079.
[http://dx.doi.org/10.1158/2159-8290.CD-19-0182] [PMID: 31109923]
[21]
Kalyukina, M.; Yosaatmadja, Y.; Middleditch, M.J.; Patterson, A.V.; Smaill, J.B.; Squire, C.J. TAS-120 cancer target binding: Defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem, 2019, 14(4), 494-500.
[http://dx.doi.org/10.1002/cmdc.201800719] [PMID: 30600916]
[22]
Lamarca, A.; Barriuso, J.; McNamara, M.G.; Valle, J.W. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J. Hepatol., 2020, 73(1), 170-185.
[http://dx.doi.org/10.1016/j.jhep.2020.03.007] [PMID: 32171892]
[23]
Roskoski, R. Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol. Res., 2023, 187, 106552.
[http://dx.doi.org/10.1016/j.phrs.2022.106552] [PMID: 36403719]
[24]
Vogel, A.; Segatto, O.; Stenzinger, A.; Saborowski, A. FGFR2 inhibition in cholangiocarcinoma. Annu. Rev. Med., 2023, 27(74), 293-306.
[http://dx.doi.org/10.1146/annurev-med-042921-024707] [PMID: 36170665]

Rights & Permissions Print Cite
Article Metrics
41
5
© 2024 Bentham Science Publishers | Privacy Policy